Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study

MLA

Onur Hurşitoğlu, et al. “Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study.” Neuropsychiatric Disease and Treatment, vol. 18, Aug. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4295349dbe32b2a662fc7e6825bf9d01&authtype=sso&custid=ns315887.

APA

Onur Hurşitoğlu, Ergul Belge Kurutas, Rebecca Strawbridge, Omer Faruk Uygur, Emrah Yildiz, & Thomas J Reilly. (2022). Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study. Neuropsychiatric Disease and Treatment, 18.

Chicago

Onur Hurşitoğlu, Ergul Belge Kurutas, Rebecca Strawbridge, Omer Faruk Uygur, Emrah Yildiz, and Thomas J Reilly. 2022. “Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study.” Neuropsychiatric Disease and Treatment 18 (August). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4295349dbe32b2a662fc7e6825bf9d01&authtype=sso&custid=ns315887.